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Abstract
Commercialization within the academic setting is associated with many challenges and barriers. Previous studies
investigating these challenges/barriers have, in general, broadly focused on multiple disciplines and, oftentimes, several
institutions simultaneously. The goal of the study presented here was to analyze a range of barriers that may be broadly
associated with commercializing academic-based cancer research. This goal was addressed via a study of the barriers
associated with cancer research commercialization at the University of Kentucky (UK). To this end, a research instrument in
the form of an electronic survey was developed. General demographic information was collected on study participants and
two research questions were addressed: 1) What are the general barriers inhibiting cancer research commercialization at
UK? and 2) Would mitigation of the barriers potentially enhance faculty engagement in commercialization activities?
Descriptive and statistical analysis of the data reveal that multiple barriers likely inhibit cancer research commercialization at
UK with expense, time, infrastructure, and lack of industry partnerships being among the most commonly cited factors. The
potential alleviation of these factors in addition to revised University policies/procedures, risk mitigation, more emphasis on
commercialization by academia research field, and increased information on how to commercialize significantly correlated
with the potential for increased commercialization activity. Furthermore, multivariate logistic regression modeling
demonstrated that research commercialization would incrementally increase as barriers to the process are removed and
that PhD-holding respondents and respondents in commercialization-supportive research fields would be more likely to
commercialize their research upon barrier removal. Overall, as with other disciplines, these data suggest that for innovations
derived from academic cancer-research to move more effectively and efficiently into the marketplace, university
administrators and external agents, such as policymakers, need to address what are well-documented and defined issues.
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Introduction
The Bayh-Dole Act, which was passed by the United States
Congress in 1980, gave academic institutions control over the
intellectual property developed by faculty, staff, and/or students as
the result of federally-sponsored research and it obligated
institutions to license intellectual property with licensing prefer-
ences going to small businesses and industries within the United
States. The Bayh-Dole Act also allowed universities and inventors
to receive royalties from commercialized technology/services [1–
4]. Prior to the Bayh-Dole Act, the United States government
owned and managed intellectual property developed at academic
institutions as the result of federal funds, and because of this
arrangement, patent protection and licensing of technology was
rarely pursued [1,2]. As the result of advancements in academic-
and industry-based research and changes in policies at the federal
and institutional levels, academic institutions have become
significant contributors to research commercialization via obtain-
ing patents, licensing intellectual property, and forming start-up
companies [5]. In fact, commercialization activity is increasing
year-over-year. For example, in 2011, the Association of
University Technology Managers indicated that surveyed institu-
tions as a whole obtained 4,700 patents (increasing 5.2% over
2010), executed over 4,800 licenses (increasing 14% over 2010),
and formed 670 start-up companies (increasing 3% over 2010).
This activity earned the surveyed institutions $2.5 billion in
income in 2011 representing a 2.6% increase over 2010 [6].
Despite a significant volume of academic-based research
commercialization, academia faces challenges to commercializing
innovations derived from its research. Challenges that have been
well-documented include: perceived risk; insufficient faculty time;
lack of financial support; policy/regulation barriers; insufficient
university commercialization infrastructure; lack of perceived
importance to the university, the research field, to faculty, or to
society; a disconnect between research and what faculty believe
could be innovative, commercializable research; unclear and
uncommon goals and benefits between faculty and university
administration; faculty questioning whether research commercial-
ization is a component of the academic mission; lack of
entrepreneurial thinking among faculty; faculty not understanding
how to commercialize their research; and lack of interaction and
collaboration between universities and industry [7–14]. These
challenges can reduce the effectiveness and efficiency of research
commercialization resulting in academia-derived innovation that
may never be commercialized to the market and thereby these
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challenges can hamper the downstream benefits that both
academia and society could reap.
This study aimed to analyze a range of barriers that may be
broadly associated with commercializing academic-based cancer
research, which is an activity of interest to a number of faculty
associated with the University of Kentucky (UK) Markey Cancer
Center. This goal was addressed via a survey of the barriers
associated with cancer research commercialization at UK. An
electronic survey was developed and used to identify areas of
opportunity for improving cancer research commercialization at
UK. Two research questions were addressed: 1) What are the
general barriers inhibiting cancer research commercialization at
UK? and 2) Would mitigation of the barriers potentially enhance
faculty engagement in commercialization activities? The data
show that multiple barriers inhibit cancer research commercial-
ization at UK. Additionally, multivariate logistic regression
modeling demonstrates: 1) the potential for increasing cancer
research commercialization at UK upon barrier removal; and 2)
that some respondents are differentially impacted by the
commercialization barriers. This analysis provides a roadmap for
the issues that need to be addressed at UK to enhance cancer
research commercialization. Additionally, given that the results are
in-line with the existing data on the major challenges associated
with academic-based research commercialization in general, these
data further suggest that university administrators and external
agents, such as policymakers, need to address a common set of
issues to make all academic research commercialization more
effective and efficient.
Methodoloy
Research Design
Similar previous studies that have broadly focused on identify-
ing general research commercialization issues guided the devel-
opment of the study presented here [7,9,14]. Of the prior research,
the study herein is modeled most closely after the study conducted
by the Atlantic Canada Opportunities Agency [7]. Inasmuch, the
methodology and design of this study was quantitative, cross-
sectional survey research.
A convenience sampling of UK faculty with interests in cancer
research was used as study participants. As such, this is a cross-
sectional study without a control population of researchers with
broader research interests. At UK, the Colleges of Agriculture,
Arts and Science, Communication and Information, Dentistry,
Engineering, Health Sciences, Medicine, Nursing, Pharmacy, and
Public Health house the majority of faculty members with
potential cancer research interests. The selection criteria for
inclusion in the study were that subjects must be UK faculty
members with cancer-related research programs and/or support
cancer research in some capacity. Subjects at the age of
approximately 30 and above and, to the extent possible, of all
genders, race, and ethnicity were recruited into the study. The
recruitment population totaled 240 faculty, and 76 faculty
participated in the study generating an overall response rate of
31.7%. The response rate for a particular question and/or
responses to a particular variable within the research instrument
did vary. For example, for questions related to research question 1,
the response rate per barrier variable ranged from 28% to 31%
(see Table S7), and for one aspect of research question 2, the
response rate was 30% (see Table S9). Text S1 and Tables S1–S6
describe the demographic profile of the study participants.
The independent variables evaluating commercialization barri-
ers and mitigating factors in this study were developed via the
review of similar prior studies and included a selection of the
various possible barriers/mitigating factors to commercializing
academic research [7,9,14]. The measured independent variables
fit into the themes of perceived risk; insufficient time; lack of
financial support; policy/regulation barriers; insufficient university
commercialization infrastructure; lack of perceived importance to
the university, the research field, to faculty, or to society; faculty
not understanding how to commercialize their research; lack of
interaction and collaboration with industry; and the complexity of
the research topic. Other measured variables included questions
addressing the scope and importance of cancer research commer-
cialization at UK in addition to other faculty demographic
information such as age, race/ethnicity, academic department,
academic rank, type of degree held, and type of research
conducted.
Instrumentation and Data Collection
As stated above, this study, including the data collection
instrument, was modeled very closely after that of similar prior
research with particular attention paid to the study by the Atlantic
Canada Opportunities Agency [7]. The data collection/research
instrument is included as supporting information (Text S2). Data
were collected and managed using the Research Electronic Data
Capture (REDCap) tool, which is available at UK. REDCap is a
secure, Internet-based study-support application [15].
Data Analysis
As indicated above, two research questions were addressed: 1)
What are the general barriers inhibiting cancer research
commercialization at UK? and 2) Would mitigation of the barriers
potentially enhance faculty engagement in commercialization
activities? The data instrumentation and collection methodology
generated quantitative data which was aggregated for analysis.
A Likert scale was used for several of the questions within the
research instrument. Descriptive statistics (frequencies and percent
response) were calculated to initially summarize the distribution of
the responses of the independent variables. The raw data (much of
which is presented in the companion supporting information) was,
in general, dichotomized (for example, yes or no; likely or not
likely; agree or not agree) for further analysis. The Fisher’s exact
test was used to explore the univariate association of barriers and
mitigating factors with faculty’s commercialization engagement,
namely whether faculty had attempted to commercialize their
research (dichotomized as yes or no) or whether faculty would
increase commercialization engagement if the barriers in the
process were removed (dichotomized as agree [strongly agree,
agree] or disagree [strongly disagree, disagree, neutral]). The
barriers and mitigating factors were collapsed into two categories –
namely agree (strongly agree, agree) or not agree (strongly
disagree, disagree, neutral).
Multivariate analysis using the logistic regression model was
employed to determine the effect of an overall cancer research
commercialization barrier score and to understand whether some
respondents are differentially impacted by different commercial-
ization barriers. The overall barrier score was calculated based on
the total number of barriers identified by each respondent and it
produced a measure of the intensity of the barriers which was then
included as an independent variable in the model. Additionally,
the model measured the association of other independent variables
– including age, gender, faculty rank, whether a respondent held a
PhD versus MD, appointment in the College of Medicine, types of
research a respondent is involved in, and the importance of
commercialization in a respondent’s research field – with the
intent to increase commercialization engagement if the barriers in
the process were removed. Model-building using forward selection
Cancer Research Commercialization Barriers
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was employed and the final model included all the variables
significantly associated with respondents’ intent to increase
commercialization engagement upon barrier removal. The
significant variables in the model are presented with odds ratios,
p-values, and 95% confidence intervals.
Ethical Considerations of Human Participants
The study design – including the informed consent process – of
this human subjects research project was reviewed and approved
by the University of Kentucky (UK) non-medical Institutional
Review Board, which is administered through the UK Office of
Research Integrity, a unit under the Office of the Vice President
for Research. UK’s human research protection program is fully
accredited by the Association for Accreditation of Human
Research Protection Programs, Inc. Respondents were consented
electronically via their engagement with the research instrument.
Via REDCap, subjects remained both anonymous and confiden-
tial as no identifying codes were collected during the data
collection stage of the study.
Results
This cross-sectional study included responses from 76 faculty
interested in cancer research at UK. The demographic profile of
the study participants is described in the companion supporting
text and tables (Text S1 and Tables S1–S6). Below, the results of
the two research questions are summarized.
Barriers Associated with Cancer Research
Commercialization
The first research question in this study was the following: What
are the general barriers inhibiting cancer research commerciali-
zation at UK? To address this question, respondents were asked to
score how important potential barriers are to inhibiting cancer
research commercialization at UK. As shown in Figure 1A,
expense (65%), time (59%), infrastructure (55%), and lack of
industry partners (46%) were the most frequently chosen barriers
that faculty felt inhibited their ability to commercialize their
research. The Fisher’s exact test was utilized to measure potential
association between the barriers and faculty’s engagement in the
commercialization continuum via the attempt to commercialize
their research (Table S4). Figure 1B shows that university policies/
procedures (58% agree versus 31% not agree), lack of industry
partnerships (54% agree versus 28% not agree), expense (53%
agree versus 17% not agree), and time (51% agree versus 25% not
agree) are significantly associated with faculty not attempting to
commercialize their research. Also of note, not being aware how to
commercialize (18% agree versus 50% not agree), limited research
application (17% agree versus 51% not agree), and having no
interest in commercializing (9% agree versus 45% not agree) do
not – to a significant level – inhibit the respondents from
attempting to commercialize their research.
Mitigation Required to Increase Cancer Research
Commercialization
The second research question in this study was the following:
Would mitigation of the barriers to research commercialization
potentially enhance faculty engagement in commercialization
activities? To address this question, respondents were simply asked
if removing the barriers identified in research question 1 would
increase their participation in research commercialization. As
shown in Table S9, the data indicate that 61% of faculty believe
that they would be more likely to participate in research
commercialization if the barriers identified in research question
1 were removed. Next, using nearly identical variables as was used
in research question 1, respondents were asked to indicate the
mitigation that would be required to (theoretically) increase their
participation in cancer research commercialization activities at
UK. Figure 2A shows that financial support (75%), improved
infrastructure (67%), protected time (67%), more industry
partnerships (63%), information on how to commercialize (63%),
allowances in industry partnership contracts (59%), and more
emphasis by academia and/or a research field (55%) were the
most frequently identified areas that faculty felt would need to be
addressed to increase their research commercialization participa-
tion. The Fisher’s exact test was utilized to measure potential
association between the mitigating factors and the potential for
enhanced research commercialization. Figure 2B shows that
allowances in industry contracts (81% agree versus 38% not
agree), more industry partnerships (80% agree versus 36% not
agree), revised university policies/procedures (80% agree versus
54% not agree), risk mitigation (80% agree versus 50% not agree),
improved infrastructure (80% agree versus 26% not agree),
financial support (78% agree versus 20% not agree), more
emphasis placed on research commercialization by academia
and/or a research field (78% agree versus 47% not agree),
information on how to commercialize (76% agree versus 46% not
agree), and protected time (76% agree versus 35% not agree) are
significantly associated with faculty being more active in research
commercialization. Also of note, acting somewhat as a control,
respondents did not agree (25% agree versus 70% not agree) – to a
significant extent – with the statement that ‘‘nothing would help’’
increase commercialization activity.
Model of the Impact of Barrier Removal
Finally, a multivariate logistic regression model was used – as
described in the Methodology section – to determine the effect of
an overall cancer research commercialization barrier score and to
understand whether some respondents are differentially impacted
by different commercialization barriers. The calculated overall
barrier score indicated that for every barrier mitigated, an
individual would be 1.4 times more likely to agree to be more
active in commercializing their research (p = 0.0008; 95%
confidence interval = 1.1–1.6). The model also indicated that
PhD-holding respondents (including PhDs and MD/PhDs) were
19 times more likely to agree to be more active in commercial-
ization when the barriers in the process were removed versus
respondents who did not hold this degree (p = 0.0004; 95%
confidence interval = 3.7–97.7). And, respondents in research
fields that are perceived to be supportive of academic research
commercialization (Table S6) were found to be 5.5 times more
likely to agree to be more active in commercialization of their
research when the barriers were removed versus respondents in
non-supportive research fields (p = 0.0219; 95% confidence
interval = 1.3–23.8). The area under the receiver operating
characteristic curve for this final model was approximately 89%,
which indicates that the model correctly classifies about 89% of the
sample into either one of the two levels of the outcome variable
(agreeing to be more active in commercialization versus not
agreeing to be so).
Discussion
The challenges/barriers associated with academic-based re-
search commercialization are well-documented and frequently
studied. In very broad terms, the most frequently cited challenges/
barriers are in the general categories of entrepreneurial history/
culture of an institution, polices, infrastructure, and industry
Cancer Research Commercialization Barriers
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Figure 1. Barriers Associated with Cancer Research Commercialization. Respondents were asked to score whether a potential barrier
(variable) is important to inhibiting their cancer research commercialization at UK. A) The percentage of respondents agreeing that a particular
variable is a barrier to the commercialization of their cancer research. The raw data for panel A is shown in Table S7. B) The comparison (by
percentage) of respondents indicating that they have attempted to commercialize their research and either agree versus not agree that a particular
variable is a barrier to commercializing their research. The raw data for panel B is shown in Table S8. * p,0.05.
doi:10.1371/journal.pone.0072268.g001
Cancer Research Commercialization Barriers
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e72268
Figure 2. Mitigation Required to Increase Cancer Research Commercialization. Respondents were asked to indicate the mitigation that
would be required to (theoretically) increase their participation in cancer research commercialization activities at UK. A) The percentage of
respondents agreeing that a particular variable is a mitigating factor that would aid in increasing the commercialization of their cancer research. The
raw data for panel A is shown in Table S10. B) The comparison (by percentage) of respondents indicating that they have attempted to commercialize
their research and either agree versus not agree that a particular mitigating factor would aid in commercializing their research. The raw data for panel
B is shown in Table S11. * p,0.05.
doi:10.1371/journal.pone.0072268.g002
Cancer Research Commercialization Barriers
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partnerships (7–14). The data presented in this current study are
in-line with these previous observations, suggesting that the
barriers to cancer research commercialization are no different
than the barriers for other disciplines. As with other general
studies, our data highlight the fact that no one barrier is likely
solely responsible for inhibiting cancer research commercializa-
tion. Specifically, expense, time, infrastructure, and lack of
industry partnerships are among the most frequently cited factors
that our respondents felt inhibit their ability to commercialize their
cancer research. Inasmuch, respondents indicated that they may
be more active in commercialization if these factors in addition to
University policies/procedures, risk, more emphasis by academia/
a research field, and information on how to commercialize were
alleviated/addressed. In fact, our multivariate logistic model
demonstrated that multiple factors would indeed need mitigated
to significantly boost cancer research commercialization as such
activity would only increase by a factor of 1.4 for each barrier
removed. Lastly, our model shows that PhD-holding faculty and
faculty working in commercialization-supportive research fields
are more likely to commercialize their research upon barrier
removal than are other types of faculty.
It is important to note that several limitations are associated
with this study. First, as a cross-sectional study, the findings may
not be generalizable to all cancer-focused faculty either at UK or
at other universities, and the findings may or may not be capable
of being generalized to other research areas. Second, as a cross-
sectional study, potential biases include subject selection bias
which could lead to data and outcome bias. Additionally, since the
study was designed to identify general challenges to cancer
research commercialization, other, perhaps more specific, chal-
lenges may not have been addressed by this analysis. Lastly, the
data was collected during a short period of time, and thus, barriers
experienced by participants outside of this data collection widow
may not have been captured. Despite these limitations, as stated
above, the data herein are consistent with previous studies and
therefore reasonable extrapolations can be made as to how these
findings are applicable to UK and other institutions.
Many academic institutions have been successful at the
commercialization process in ways that have led to increased
commercialization activity and a greater volume of activity
compared to what occurs at other universities. For example, in
2011, out of 186 respondents to the Association of University
Technology Managers’ annual survey, 54 received more patents
than the University of Kentucky (UK), 119 executed more
licenses, 25 formed more start-up companies, and 90 generated
more income from their commercialization activity than did UK
[6]. Many of the highly commercializing institutions are being
more successfully because they have navigated the barriers in the
commercialization process in ways that facilitate enhanced
commercialization activity [6,8,12]. As such, the data from this
study can act as a roadmap for improving cancer-research
commercialization at UK and perhaps at other institutions
considering that our data are in-line with previous, general
studies. For example, UK has 2 employees dedicated to
intellectual property development whereas many other institutions
have more staff dedicated to commercialization activities [6]. Such
differences could be fairly easily reconciled, but these types of
infrastructure-related issues are largely dictated by a university’s
mission (or culture) regarding commercialization and the previous
volume of commercialization activity within a university [8,12].
The commercialization- and economic development-associated
offices at UK have recently been organizationally restructured and
the data from this study have been presented to the Vice President
for Research, so these events may represent an opportunity to
enhance the commercialization enterprise at the university.
Despite the fact that until now, this article has had an undertone
of promoting an increase in academic-based research commer-
cialization, this topic is under much international debate mostly
over the ethical nature of such activity. The role of the university
in the pursuit of general knowledge versus intellectual property
protection and use thereof, general conflicts of interest potentially
created by academic commercialization, and the role of profits
from commercialization activities within the university setting are
some of the issues central to the ethical debate [16]. Profits and
incentives aimed at increasing research commercialization within
academia have been argued to have the potential for stimulating
the commercialization of ‘‘marginal inventions’’ and shifting
universities from the pursuit of basic knowledge to the pursuit of
only what has the greatest marketplace potential [17,18].
Overall, the data herein adds to the current literature
documenting the common and well-defined issues related to
academic-based commercialization, as it appears that cancer
research commercialization barriers are generally no different
than those associated with other disciplines. As such, these data
further outline the issues that university administrators and
external agents, such as policymakers, need to address in order
to move academic-derived research more effectively and efficiently
into the marketplace. Notwithstanding, given the ethical issues
related to academic-based research commercialization, perhaps
some universities do not know how to devise commercialization
practices and infrastructure in ways that will satisfy all the
stakeholders and promote a healthy amount/balance of commer-
cialization activity versus the general pursuit of knowledge. As
such, prior to pursuing additional research in the area of the
barriers/challenges associated with academic research commer-
cialization, perhaps efforts in this field should shift to elucidating
whether academic-based research commercialization is eroding or
damaging the mission of academic research versus providing
positive benefits to academia and society.
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